Tenax Therapeutics Stock Forecast, Price & News

+0.01 (+0.54 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume54,921 shs
Average Volume90,309 shs
Market Capitalization$27.99 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TENX News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Tenax Therapeutics logo

About Tenax Therapeutics

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company develops levosimendan, which completed a phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction; and Imatinib, a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.41 out of 5 stars

Medical Sector

1495th out of 4,434 stocks

Pharmaceutical Preparations Industry

717th out of 1,738 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

Is Tenax Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tenax Therapeutics stock.
View analyst ratings for Tenax Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Tenax Therapeutics?

Wall Street analysts have given Tenax Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tenax Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Tenax Therapeutics' next earnings date?

Tenax Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 16th 2021.
View our earnings forecast for Tenax Therapeutics

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) issued its quarterly earnings results on Wednesday, May, 19th. The specialty pharmaceutical company reported ($1.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $1.43.
View Tenax Therapeutics' earnings history

How has Tenax Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Tenax Therapeutics' stock was trading at $1.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TENX shares have increased by 79.8% and is now trading at $1.87.
View which stocks have been most impacted by COVID-19

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Tenax Therapeutics shares reverse split before market open on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for TENX?

1 brokers have issued twelve-month price targets for Tenax Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Tenax Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 167.4% from the stock's current price.
View analysts' price targets for Tenax Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the following people:
  • Mr. Anthony A. DiTonno, CEO & Director (Age 73, Pay $662.2k)
  • Mr. Michael B. Jebsen, Pres & CFO (Age 50, Pay $525.83k)
  • Ms. Nancy J. M. Hecox, Exec. VP of Legal Affairs, Gen. Counsel & Corp. Sec.
  • Mr. Doug Randall, Exec. VP of Commercial & Bus. Operations
  • Dr. Douglas Hay, Sr. VP of Regulatory Affairs
  • Dr. Stuart Rich M.D., Chairman of Scientific Advisory Board, Chief Medical Officer & Director (Age 71)

Who are some of Tenax Therapeutics' key competitors?

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

How do I buy shares of Tenax Therapeutics?

Shares of TENX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenax Therapeutics' stock price today?

One share of TENX stock can currently be purchased for approximately $1.87.

How much money does Tenax Therapeutics make?

Tenax Therapeutics has a market capitalization of $27.99 million. The specialty pharmaceutical company earns $-9,850,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Tenax Therapeutics have?

Tenax Therapeutics employs 9 workers across the globe.

When was Tenax Therapeutics founded?

Tenax Therapeutics was founded in 1967.

What is Tenax Therapeutics' official website?

The official website for Tenax Therapeutics is

Where are Tenax Therapeutics' headquarters?

Tenax Therapeutics is headquartered at ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-855-2100 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.